B Cell-Activating Factor (BAFF) and Ubiquitin Enzyme A20 as Functional Proteins in Targeted Therapy on Patients with Systemic Lupus Erythematosus
Abstract
BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by inflammation. The pathogenesis of SLE involves key proteins, including B cell-activating factor (BAFF) and the ubiquitin enzyme A20, both serving as negative regulators of inflammation and contributing to B cell homeostasis. In this review, focused on interventions directed at BAFF and the A20 enzyme, utilizing monoclonal antibodies either independently or in conjunction with conventional therapy for SLE patients.
METHODS: A literature search was conducted on the PubMed platform by combining various terms, including "B-cells activating factor", "TNFAIP3 protein (human)", "therapeutics" or "drug therapy", and "lupus erythematosus, systemic" (limited to the last 10 years). From total of 104 articles discovered in thr search, the total number of articles collected after being filtered was 27 articles.
RESULTS: Clinical development and evaluation have been conducted regarding the use of appropriate therapy for SLE patients. Selective BAFF inhibitor has been tested in clinical trials as a blocking agent in BAFF receptor (BAFF-R) and signaling nuclear factor-kappaB (NF-κB) by A20 bindings to inhibit the activation of autoreactive B cells. Just like other antimonoclonal therapies, BAFF and the A20 enzyme can be used as therapeutic targets with a single use or combined with the standard therapy in patients with SLE. In addition, the use of BAFF and A20 also shown to have safe side effects in patients with SLE.
CONCLUSION: BAFF protein and A20 enzyme present promising therapeutic targets for managing autoimmune diseases like SLE. Therapeutic interventions can be administered individually or in conjunction with standard treatments.
KEYWORDS: systemic lupus erythematosus, therapeutic targets, BAFF, A20
Full Text:
PDFReferences
Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M. The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int. 2015; 112(25): 423-32, CrossRef.
Crampton SP, Morawski PA, Bolland S. Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus. DMM Dis Model Mech. 2014; 7(9): 1033-46, CrossRef.
Lee WS, Amengual O. B cells targeting therapy in the management of systemic lupus erythematosus. Immunol Med. 2020; 43(1): 16-35, CrossRef.
Manuaba IARW, Suryana K, Bakta IM, Sudarmaja IM. Serum DNase1, sTNFR1 and sTNFR2 as risk factors for lupus nephritis in systemic lupus erythematosus patients. Indones Biomed J. 2024; 16(3): 263-8, CrossRef.
Suntoko B, Hadisaputro S, Kalim H, Hadi S, Warlisti IV. A double-blind, randomized controlled trial of hydroxychloroquine for cognitive dysfunction and inflammatory biomarkers in systemic lupus erythematosus patients in Indonesia. Indones Biomed J. 2023; 15(4): 354-61, CrossRef.
Kandane-Rathnayake R, Golder V, Louthrenoo W, Luo SF, Jan Wu YJ, Li Z, et al. Development of the Asia Pacific Lupus Collaboration cohort. Int J Rheum Dis. 2019; 22(3): 425-33, CrossRef.
Elalouf O, Keeling SO, Touma Z. Subcutaneous belimumab in the treatment of systemic lupus erythematosus. Immunotherapy. 2018; 10(13): 1163-73, CrossRef.
Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017; 36(1): 3-19, CrossRef.
Howe HS, Thong BYH, Kong KO, Chng HH, Lian TY, Chia FL, et al. Associations of B cell-activating factor (BAFF) and anti-BAFF autoantibodies with disease activity in multi-ethnic Asian systemic lupus erythematosus patients in Singapore. Clin Exp Immunol. 2017; 189(3): 298-303, CrossRef.
Jackson SW, Scharping NE, Jacobs HM, Wang S, Chait A, Rawlings DJ. Cutting edge: BAFF overexpression reduces atherosclerosis via TACI-dependent B cell activation. J Immunol. 2016; 197(12): 4529-34, CrossRef.
Tsiantoulas D, Sage AP, Mallat Z, Binder CJ. Targeting B cells in atherosclerosis: Closing the gap from bench to bedside. Arterioscler Thromb Vasc Biol. 2015; 35(2): 296-302, CrossRef.
Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther. 2015; 9: 333-47, CrossRef.
Vitri RY, Wachjudi RG, Ghassani NG, Hamijoyo L. Correlation of B-cell-activating factor levels and diseases activity in systemic lupus erythematosus patients. Indian J Rheumatol. 2021; 16(1): 13-7, CrossRef.
Tejasvi T, Stuart PE, Chandran V, Voorhees JJ, Gladman DD, Rahman P, et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol. 2012; 132(3 Part 1): 593-600, CrossRef.
Mele A, Cervantes JR, Chien V, Friedman D, Ferran C. Single nucleotide polymorphisms at the tnfaip3/a20 locus and susceptibilitylresistance to inflammatory and autoimmune diseases. Adv Exp Med Biol. 2014; 809: 163-83, CrossRef.
Ma A, Malynn BA. A20: Linking a complex regulator of ubiquitylation to immunity and human disease. 2013; 12(11): 774-85, CrossRef.
Almaden JV, Tsui R, Liu YC, Birnbaum H, Shokhirev MN, Ngo KA, et al. A Pathway switch directs BAFF signaling to distinct NFκB transcription factors in maturing and proliferating B cells. Cell Rep. 2014; 9(6): 2098-111, CrossRef.
Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): Results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018; 77(6): 883-9, CrossRef.
Vincent FB, Morand EF, Schneider P, MacKay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014; 10(6): 365-73, CrossRef.
Scholz JL, Oropallo MA, Sindhava V, Goenka R, Cancro MP. The role of B lymphocyte stimulator in B cell biology: Implications for the treatment of lupus. Lupus. 2013; 22(4): 350-60, CrossRef.
Lee YH, Song GG. Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: A Bayesian network meta-analysis of randomized controlled trials. Lupus. 2018; 27(1): 112-9, CrossRef.
La Cava A. Targeting the BLyS-APRIL signaling pathway in SLE. Clin Immunol. 2013; 148(3): 322-7, CrossRef.
Ortiz-Aljaro P, Montes-Cano MA, García-Lozano JR, Aquino V, Carmona R, Perez-Florido J, et al. Protein and functional isoform levels and genetic variants of the BAFF and APRIL pathway components in systemic lupus erythematosus. Sci Rep. 2022; 12(1): 11219, CrossRef.
Cai LQ, Wang ZX, Lu WS, Han JW, Sun LD, Du WH, et al. A single-nucleotide polymorphism of the TNFAIP3 gene is associated with systemic lupus erythematosus in Chinese Han population. Mol Biol Rep. 2010; 37(1): 389-94, CrossRef.
Yu MP, Xu XS, Zhou Q, Deuitch N, Lu MP. Haploinsufficiency of A20 (HA20): Updates on the genetics, phenotype, pathogenesis and treatment. World J Pediatr. 2020; 16(6): 575-84, CrossRef.
Malynn BA, Ma A. A20: A multifunctional tool for regulating immunity and preventing disease. Cell Immunol. 2019; 340: 103914, CrossRef.
Momtazi G, Lambrecht BN, Naranjo JR, Schock BC. Regulators of A20 (TNFAIP3): New drug-able targets in inflammation. Am J Physiol Lung Cell Mol Physiol. 2019; 316(3): L456-69, CrossRef.
Odqvist L, Jevnikar Z, Riise R, Öberg L, Rhedin M, Leonard D, et al. Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(10): 1363-70, CrossRef.
Stohl W. Biologic differences between various inhibitors of the BLyS/ BAFF pathway: Should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep. 2012; 14(4): 303-9, CrossRef.
Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020; 383(12): 1117-28, CrossRef.
Wallace DJ, Hobbs K, Clowse MEB, Petri M, Strand V, Pike M, et al. Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: Results from an open-label extension study. Arthritis Care Res. 2016; 68(4): 534-43, CrossRef.
Chamberlain C, Colman PJ, Ranger AM, Burkly LC, Johnston GI, Otoul C, et al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profile. Ann Rheum Dis. 2017; 76(11): 1837-44, CrossRef.
Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, et al. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Lupus. 2018; 27(9): 1489-98, CrossRef.
Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Roth D. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial. Mod Rheumatol. 2020; 30(2): 313-20, CrossRef.
Ramachandran S, Parks D, Kurtinecz M, Roth DA, Alfonso-Cristancho R. An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity. J Comp Eff Res. 2018; 7(6): 581-93, CrossRef.
Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents. Front Med. 2020: 7: 303, CrossRef.
Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 2021; 73(1): 121-31, CrossRef.
Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020; 79(10): 1340-8, CrossRef.
Dubey AK, Handu SS, Dubey S, Sharma P, Sharma KK, Ahmed QM. Belimumab: First targeted biological treatment for systemic lupus erythematosus. J Pharmacol Pharmacother. 2011; 2(4): 317-9, CrossRef.
Stolyar L, Lahita RG, Panush RS. Rituximab use as induction therapy for lupus nephritis: A systematic review. Lupus. 2020; 29(8): 892-912, CrossRef.
Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: A prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019; 9(12): e032569, CrossRef.
Hennessey A, Lukawska J, Cambridge G, Isenberg D, Leandro M. Adverse infusion reactions to rituximab in systemic lupus erythematosus: A retrospective analysis. BMC Rheumatol. 2019; 3(1): 32, CrossRef.
Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int. 2016; 89(1): 235-42, CrossRef.
Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman MH, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015; 17(1): 215, CrossRef.
Rovin BH, Dooley MA, Radhakrishnan J, Ginzler EM, Forrester TD, Anderson PW. The impact of tabalumab on the kidney in systemic lupus erythematosus: Results from two phase 3 randomized, clinical trials. Lupus. 2016; 25(14): 1597-601, CrossRef.
Witcher J, Fleischmann R, Chindalore VL, Hansen RJ, Hu L, Radtke D, et al. Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus. Br J Clin Pharmacol. 2016; 81(5): 908-17, CrossRef.
Merrill JT, Van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: Results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled stu. Ann Rheum Dis. 2016; 75(2): 332-40, CrossRef.
Rovin BH, Dooley MA, Radhakrishnan J, Ginzler EM, Forrester TD, Anderson PW. The impact of tabalumab on the kidney in systemic lupus erythematosus: Results from two phase 3 randomized, clinical trials. Lupus. 2016; 25(14): 1597-601, CrossRef.
Deng J, Luo L, Zhu L, Xie H, Xie H. Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: A metaanalysis of randomized controlled trials. Turkish J Med Sci. 2018; 48(5): 901-10, CrossRef.
Hannah J, Casian A, D'Cruz D. Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. Autoimmun Rev. 2016; 15(1): 93-101, CrossRef.
Mok CC, Ho LY, Ying SKY, Leung MC, To CH, Ng WL. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis. 2020; 79(8): 1070-6, CrossRef.
Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, Van Vollenhoven RF, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013; 65(10): 2661-71, CrossRef.
Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013; 65(9): 2368-79, CrossRef.
Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: Current evidence and future prospects. Ther Adv Neurol Disord. 2016; 9(1): 44-52, CrossRef.
Maurer B, Bosanac I, Shia S, Kwong M, Corpuz R, Vandlen R, et al. Structural basis of the broadly neutralizing anti-interferon-α antibody rontalizumab. Protein Sci. 2015; 24(9): 1440-50, CrossRef.
Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2015; 75(1): 196-202, CrossRef.
Burge DJ, Eisenman J, Byrnes-Blake K, Smolak P, Lau K, Cohen SB, et al. Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled study. Lupus. 2017; 26(8): 825-34, CrossRef.
Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014; 73(1): 183-90, CrossRef.
Furie RA, Bruce IN, Dörner T, Leon MG, Leszczyński P, Urowitz M, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatol. 2021; 60(11): 5397-407, CrossRef.
Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, et al. Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018; 70(8): 1256-64, CrossRef.
Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Struemper H, et al. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial. Mod Rheumatol. 2019; 29(3): 452-60, CrossRef.
Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018; 77(3): 355-63, CrossRef.
Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus. Lupus. 2016; 25(14): 1587-96, CrossRef.
DOI: https://doi.org/10.18585/inabj.v16i5.3161
Copyright (c) 2024 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
